BioSpace News Archive

XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets.

Sonoma Pharmaceuticals, Inc. today announced financial results for fiscal year 2023 and the fourth quarter ended March 31, 2023.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CD388, Cidara’s novel drug-Fc conjugate (DFC) candidate.

Volta Medical today announced initiation of Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion (RESTART), an interventional clinical trial to be conducted at 16 US and 5 EU sites, evaluating the use of Volta’s AI ablation solution in recurrent-AF patients who failed previous ablations and are now undergoing Volta-supported ablation.

Seelos Therapeutics, Inc. today announced the close of enrollment of its registration directed study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD).

BioMarin Pharmaceutical Inc. today announced it will present new data from the ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy clinical trial program.

The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute, for her seminal discovery that a mutation in a specific human gene causes systemic lupus erythematosus, uncovering an important target for the development of novel treatment.

Inhibikase Therapeutics, Inc. today announced that it has selected the bioequivalent dose of IkT-001Pro, the Company’s prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib (marketed as Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) and provided an update on its ‘501' bioequivalence study.

Eyenuk has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras.

Palleon Pharmaceuticals today announced that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform.